A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: The Cleveland Clinic experience

Journal of Thoracic Oncology

Volumn 4, Issue 8, 2009, Pages 976-982

  Stephans, Kevin L ^a   Djemil, Toufik ^a   Reddy, Chandana A ^a   Gajdos, Stephen M ^a   Kolar, Matthew ^a   Mason, David ^a   Murthy, Sudish ^a   Rice, Thomas W ^a   Mazzone, Peter ^a   MacHuzak, Michael ^a   Mekhail, Tarek ^a   Videtic, Gregory M M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Dose fractionation; Medically inoperable; Stage I lung cancer; Stereotactic body radiotherapy

Indexed keywords

AGED; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISTANT METASTASIS; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION PNEUMONIA; TREATMENT FAILURE;

EID: 68349086672     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181adf509     Document Type: Article

References (34)

1. Baumann P, Nyman J, Lax I, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 2006;45:787-795. (Pubitemid 44423123)
2. Fukumoto S, Shirato H, Shimzu S, et al. Small-volume image-guided radiotherapy using hypofractionated, coplanar, and noncoplanar multiple fields for patients with inoperable Stage I nonsmall cell lung carcinomas. Cancer 2002;95:1546-1553.
3. Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I nonsmall- cell lung cancer. Int J Radiat Oncol Biol Phys 2008;70:685-692.
4. McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys 2005;63:1010-1015. (Pubitemid 41505277)
5. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005;63:1427-1431. (Pubitemid 41628038)
6. Ng AW, Tung SY, Wong VY. Hypofractionated stereotactic radiotherapy for medically inoperable stage I non-small cell lung cancer-report on clinical outcome and dose to critical organs. Radiother Oncol 2008; 87:24-28.
7. Nyman J, Johansson KA, Hulten U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer-mature results for medically inoperable patients. Lung Cancer 2006;51:97-103. (Pubitemid 43088629)
8. Onimaru R, Shirato H, Shimizu S, et al. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys 2003;56:126-135. (Pubitemid 36403684)
9. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2:S94-S100. (Pubitemid 47183602)
10. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006;24:4833-4839. (Pubitemid 46630909)
11. Uematsu M, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001;51:666-670. (Pubitemid 32951783)
12. Xia T, Li H, Sun Q, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-smallcell lung cancer. Int J Radiat Oncol Biol Phys 2006;66:117-125. (Pubitemid 44175645)
13. Zimmermann FB, Geinitz H, Schill S, et al. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol 2006;45:796-801. (Pubitemid 44423124)
14. Rosenzweig KE, Fox JL, Yorke E, et al. Results of a phase I doseescalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer 2005;103: 2118-2127. (Pubitemid 40605120)
15. Sibley GS. Radiotherapy for patients with medically inoperable stage I nonsmall cell lung carcinoma: smaller volumes and higher doses-a review. Cancer 1998;82:433-438.
16. Fowler JF, Tome WA, Fenwick JD, Mehta MP. A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys 2004;60:1241-1256.
17. Guerrero M, Li XA. Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol 2004;49:4825-4835. (Pubitemid 39433509)
18. Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:847-852. (Pubitemid 351199730)
19. Ohashi T, Takeda A, Shigematsu N, et al. Differences in pulmonary function before vs. 1 year after hypofractionated stereotactic radiotherapy for small peripheral lung tumors. Int J Radiat Oncol Biol Phys 2005;62:1003-1008. (Pubitemid 40884410)
20. Dunlap NE, Biederman GB, Yang W, et al. Chest wall volume receiving more than 30 Gy predicts risk of severe pain and/or rib fracture following lung SBRT. Int J Radiat Oncol Biol Phys 2008:S36.
21. Voroney JPJ, Hope A, Dahele MR, et al. Pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2008:S35-S36.
22. Radiation Therapy Oncology Group. Available at: http://www.rtog.org/ members/protocols/0236/0236.pdf. Accessed December 31, 2008.
23. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004;101:1623-1631. (Pubitemid 39318910)
24. Yaes RJ, Patel P, Maruyama Y. On using the linear-quadratic model in daily clinical practice. Int J Radiat Oncol Biol Phys 1991;20:1353-1362.
25. Wulf J, Baier K, Mueller G, Flentje MP. Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol 2005;77:83-87. (Pubitemid 41503394)
26. Guckenberger M, Wulf J, Mueller G, et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 2009; 74:47-54.
27. Guckenberger M, Wilbert J, Krieger T, et al. Four-dimensional treatment planning for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2007;69:276-285. (Pubitemid 47247525)
28. Onimaru R, Fujino M, Yamazaki K, et al. Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:374-381.
29. Beitler JJ, Badine EA, El-Sayah D, et al. Stereotactic body radiation therapy for nonmetastatic lung cancer: an analysis of 75 patients treated over 5 years. Int J Radiat Oncol Biol Phys 2006;65:100-106.
30. Fuwa N, Mitsudomi T, Daimon T, et al. Factors involved in lymph node metastasis in clinical stage I non-small cell lung cancer-from studies of 604 surgical cases. Lung Cancer 2007;57:311-316. (Pubitemid 47285429)
31. Hoopes DJ, Tann M, Fletcher JW, et al. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer 2007;56:229-234. (Pubitemid 46590486)
32. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003;124:1946-1955. (Pubitemid 37433596)
33. Yamashita H, Nakagawa K, Nakamura N, et al. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol 2007;2:21.
34. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;285:1441-1446.